Understanding how high-risk acute myeloid leukemia resists treatment
Mechanism of Therapy in high-risk AML
This study is looking into why some patients with high-risk acute myeloid leukemia (AML) don’t respond well to treatment, focusing on certain genes and proteins, so that doctors can find better ways to help you fight this tough blood cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cincinnati Childrens Hosp Med Ctr NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-10874656 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind treatment resistance in high-risk acute myeloid leukemia (AML), a severe form of blood cancer. The team focuses on specific genetic mutations and proteins that contribute to the disease's aggressive nature and poor response to standard therapies. By examining the roles of c-FOS and DUSP1, the researchers aim to identify new strategies to enhance the effectiveness of existing treatments. Patients may benefit from insights that could lead to more effective therapies tailored to their specific genetic profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with high-risk acute myeloid leukemia, particularly those with mutations in genes like MLL, FLT3, DNMT3A, and P53.
Not a fit: Patients with low-risk acute myeloid leukemia or those without the specific genetic mutations associated with high-risk AML may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for patients with high-risk AML.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
Cincinnati, United States
- Cincinnati Childrens Hosp Med Ctr — Cincinnati, United States (Active)
Researchers
- Principal investigator: Azam, Mohammad — Cincinnati Childrens Hosp Med Ctr
- Study coordinator: Azam, Mohammad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.